Finally, our results led us to evaluate the efficacy of the compound ZINC217108151 to: (1) inhibit the proliferation of certain leukemia cell lines; (2) inhibit the phosphorylation of the p210 BCR-ABL tyrosine; and (3) affect the activity of the downstream proteins, STAT5 and Crkl, which are activated by BCR-ABL. Here, ABL1 is linked to leukemia.